Phaseline

Companies › Aptose Biosciences

Aptose Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tuspetinib (HM43239)
FLT3 inhibitor
FLT3Phase 1Leukemia, Myeloid, AcuteNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03850574Tuspetinib (HM43239)Phase 1Leukemia, Myeloid, AcuteOncologyNov 2026

Targets

FLT3 (1)

Companies with the same targets

Daiichi Sankyo Sunshine Lake Pharma Ryvu Therapeutics Bristol-Myers Squibb Novartis Cullinan Therapeutics Etnova Therapeutics Swedish Orphan Biovitrum Theradex Jiangsu HengRui Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.